Icometrix Gets First CPT III Code Issued by AMA for AI Brain MRI Software
Reportedly receiving the first Current Procedural Terminology (CPT) III code from the American Medical Association (AMA) for artificial intelligence (AI)-enabled brain magnetic resonance imaging (MRI) software, Icometrix says its adjunctive quantification software can be utilized for diagnosis and assessment of conditions ranging from Alzheimer’s disease and epilepsy to stroke and dementia.
Creating a potential path for reimbursement, the American Medical Association (AMA) has issued a Current Procedural Terminology (CPT) III code for the use of icometrix’s artificial intelligence (AI)-powered brain magnetic resonance imaging (MRI) quantification software.
Icometrix, which has five Food and Drug Administration (FDA)-cleared AI software applications for brain MRI and computed tomography (CT), said the CPT III code is the first one issued for adjunctive AI quantification of brain MRI scans.
“Precision medicine is vital for improving treatment of neurological conditions, and especially for multiple sclerosis,” noted Tim Coetzee, PhD, the chief advocacy, services, and science officer at the National Multiple Sclerosis Society. “This recognition creates a path for icometrix’s innovative technology to be integrated into the management of multiple sclerosis (MS) and takes us one step closer to a future where precision medicine guides treatment decisions.”
Icobrain ms, one of the aforementioned AI software applications, facilitates objective quantification and tracking of white matter hyperintensities on FLAIR, TI MRI and contrast-enhanced T1 MRI, according to icometrix. The company added that its portfolio of AI-enabled neuroimaging software can be utilized in the diagnosis and assessment of treatment for conditions ranging from Alzheimer’s disease and MS to stroke and epilepsy.
Can Abbreviated Breast MRI Have an Impact in Assessing Post-Neoadjuvant Chemotherapy Response?
April 24th 2025New research presented at the Society for Breast Imaging (SBI) conference suggests that abbreviated MRI is comparable to full MRI in assessing pathologic complete response to neoadjuvant chemotherapy for breast cancer.
Clarius Mobile Health Unveils Anterior Knee Feature for Handheld Ultrasound
April 23rd 2025The T-Mode Anterior Knee feature reportedly offers a combination of automated segmentation and real-time conversion of grayscale ultrasound images into color-coded visuals that bolster understanding for novice ultrasound users.
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
Meta-Analysis Shows Merits of AI with CTA Detection of Coronary Artery Stenosis and Calcified Plaque
April 16th 2025Artificial intelligence demonstrated higher AUC, sensitivity, and specificity than radiologists for detecting coronary artery stenosis > 50 percent on computed tomography angiography (CTA), according to a new 17-study meta-analysis.
